Rainer Kraehenmann1,2, Dan Pokorny3, Leonie Vollenweider4, Katrin H Preller4, Thomas Pokorny4, Erich Seifritz5, Franz X Vollenweider4. 1. Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland. r.kraehenmann@bli.uzh.ch. 2. Neuropsychopharmacology and Brain Imaging, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Lenggstrasse 31, 8032, Zurich, Switzerland. r.kraehenmann@bli.uzh.ch. 3. Department of Psychosomatic Medicine and Psychotherapy, University of Ulm, Ulm, Germany. 4. Neuropsychopharmacology and Brain Imaging, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Lenggstrasse 31, 8032, Zurich, Switzerland. 5. Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.
Abstract
RATIONALE: Accumulating evidence indicates that the mixed serotonin and dopamine receptor agonist lysergic acid diethylamide (LSD) induces an altered state of consciousness that resembles dreaming. OBJECTIVES: This study aimed to test the hypotheses that LSD produces dreamlike waking imagery and that this imagery depends on 5-HT2A receptor activation and is related to subjective drug effects. METHODS:Twenty-five healthy subjects performed an audiorecorded guided mental imagery task 7 h after drug administration during three drug conditions: placebo, LSD (100 mcg orally) and LSD together with the 5-HT2A receptor antagonist ketanserin (40 mg orally). Cognitive bizarreness of guided mental imagery reports was quantified as a standardised formal measure of dream mentation. State of consciousness was evaluated using the Altered State of Consciousness (5D-ASC) questionnaire. RESULTS:LSD, compared with placebo, significantly increased cognitive bizarreness (p < 0.001). The LSD-induced increase in cognitive bizarreness was positively correlated with the LSD-induced loss of self-boundaries and cognitive control (p < 0.05). Both LSD-induced increases in cognitive bizarreness and changes in state of consciousness were fully blocked by ketanserin. CONCLUSIONS:LSD produced mental imagery similar to dreaming, primarily via activation of the 5-HT2A receptor and in relation to loss of self-boundaries and cognitive control. Future psychopharmacological studies should assess the differential contribution of the D2/D1 and 5-HT1A receptors to cognitive bizarreness.
RCT Entities:
RATIONALE: Accumulating evidence indicates that the mixed serotonin and dopamine receptor agonist lysergic acid diethylamide (LSD) induces an altered state of consciousness that resembles dreaming. OBJECTIVES: This study aimed to test the hypotheses that LSD produces dreamlike waking imagery and that this imagery depends on 5-HT2A receptor activation and is related to subjective drug effects. METHODS: Twenty-five healthy subjects performed an audiorecorded guided mental imagery task 7 h after drug administration during three drug conditions: placebo, LSD (100 mcg orally) and LSD together with the 5-HT2A receptor antagonist ketanserin (40 mg orally). Cognitive bizarreness of guided mental imagery reports was quantified as a standardised formal measure of dream mentation. State of consciousness was evaluated using the Altered State of Consciousness (5D-ASC) questionnaire. RESULTS: LSD, compared with placebo, significantly increased cognitive bizarreness (p < 0.001). The LSD-induced increase in cognitive bizarreness was positively correlated with the LSD-induced loss of self-boundaries and cognitive control (p < 0.05). Both LSD-induced increases in cognitive bizarreness and changes in state of consciousness were fully blocked by ketanserin. CONCLUSIONS: LSD produced mental imagery similar to dreaming, primarily via activation of the 5-HT2A receptor and in relation to loss of self-boundaries and cognitive control. Future psychopharmacological studies should assess the differential contribution of the D2/D1 and 5-HT1A receptors to cognitive bizarreness.
Authors: Gerhard Dammann; Kenneth M Dürsteler-Macfarland; Hannes Strasser; Gregory E Skipper; Gerhard A Wiesbeck; Friedrich Martin Wurst Journal: Psychiatr Danub Date: 2014-03 Impact factor: 1.063
Authors: J C Gillin; W Jernajczyk; D C Valladares-Neto; S Golshan; M Lardon; S M Stahl Journal: Psychopharmacology (Berl) Date: 1994-12 Impact factor: 4.530
Authors: Suresh D Muthukumaraswamy; Robin L Carhart-Harris; Rosalyn J Moran; Matthew J Brookes; Tim M Williams; David Errtizoe; Ben Sessa; Andreas Papadopoulos; Mark Bolstridge; Krish D Singh; Amanda Feilding; Karl J Friston; David J Nutt Journal: J Neurosci Date: 2013-09-18 Impact factor: 6.167
Authors: Robin L Carhart-Harris; Suresh Muthukumaraswamy; Leor Roseman; Mendel Kaelen; Wouter Droog; Kevin Murphy; Enzo Tagliazucchi; Eduardo E Schenberg; Timothy Nest; Csaba Orban; Robert Leech; Luke T Williams; Tim M Williams; Mark Bolstridge; Ben Sessa; John McGonigle; Martin I Sereno; David Nichols; Peter J Hellyer; Peter Hobden; John Evans; Krish D Singh; Richard G Wise; H Valerie Curran; Amanda Feilding; David J Nutt Journal: Proc Natl Acad Sci U S A Date: 2016-04-11 Impact factor: 12.779
Authors: Landon M Klein; Nicholas V Cozzi; Paul F Daley; Simon D Brandt; Adam L Halberstadt Journal: Neuropharmacology Date: 2018-02-27 Impact factor: 5.250
Authors: Simon D Brandt; Pierce V Kavanagh; Brendan Twamley; Folker Westphal; Simon P Elliott; Jason Wallach; Alexander Stratford; Landon M Klein; John D McCorvy; David E Nichols; Adam L Halberstadt Journal: Drug Test Anal Date: 2017-07-27 Impact factor: 3.345
Authors: Anya K Bershad; Scott T Schepers; Michael P Bremmer; Royce Lee; Harriet de Wit Journal: Biol Psychiatry Date: 2019-06-03 Impact factor: 13.382
Authors: Adam L Halberstadt; Landon M Klein; Muhammad Chatha; Laura B Valenzuela; Alexander Stratford; Jason Wallach; David E Nichols; Simon D Brandt Journal: Psychopharmacology (Berl) Date: 2018-10-08 Impact factor: 4.530
Authors: Adam K Klein; Muhammad Chatha; Lauren J Laskowski; Emilie I Anderson; Simon D Brandt; Stephen J Chapman; John D McCorvy; Adam L Halberstadt Journal: ACS Pharmacol Transl Sci Date: 2020-12-14